Indian journal of cancer最新文献

{"title":"Pooled analysis of heterogeneous treatment groups limits interpretation of outcomes in the reported interstitial brachytherapy series.","authors":"Gautam Vydia Vedagiri","doi":"10.4103/ijc.ijc_330_26","DOIUrl":"10.4103/ijc.ijc_330_26","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"207-208"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-sectional validation of a breast cancer KAP scale for urban Indian women using social media.","authors":"Nibha Sinha","doi":"10.4103/ijc.ijc_359_26","DOIUrl":"https://doi.org/10.4103/ijc.ijc_359_26","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer among women in India, particularly among urban women, yet awareness and early detection remain inadequate. Addressing this gap requires reliable, culturally appropriate tools to measure awareness levels and to promote targeted interventions. With the growing influence of digital media, social platforms offer a powerful channel for health communication. This study aimed to validate a breast cancer knowledge, attitude, and practice (KAP) scale specifically designed for social media-active urban Indian women.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among a sample of women aged 18 years and above from the Delhi-National Capital Region. The 542 completed questionnaires were analyzed using confirmatory factor analysis (CFA) and reliability tests to validate the scale. The 36-item instrument assessed three domains: knowledge (risk factors, symptoms, and screening practices), attitude, and preventive practices. Content validity was established through expert evaluation, construct validity through CFA, and internal consistency through Cronbach's alpha.</p><p><strong>Results: </strong>The CFA results demonstrated a good model fit. All items exhibited satisfactory factor loadings, with composite reliability values exceeding 0.70 and average variance extracted (AVE) values above 0.50, confirming convergent validity. Discriminant validity was also achieved as the AVE square roots were greater than inter-construct correlations. The overall Cronbach's alpha of 0.87 indicated high reliability.</p><p><strong>Conclusion: </strong>The study provides a psychometrically tested tool to assess awareness (knowledge, attitude and practice) of breast cancer among digitally connected urban women. It can be used to identify knowledge gaps and evaluate the effectiveness of awareness campaigns.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"191-199"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prediction of anthracycline-induced cardiotoxicity: Further insights.","authors":"Ankur Jain","doi":"10.4103/ijc.ijc_379_26","DOIUrl":"10.4103/ijc.ijc_379_26","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"205-206"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Unveiling the rare, interesting series of malignant mesenchymal tumors of the kidney in a regional cancer care institute in South India.","authors":"","doi":"10.4103/ijc.ijc_518_26","DOIUrl":"10.4103/ijc.ijc_518_26","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"212"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India.","authors":"Anuradha Mehta, Debdeep Samaddar, Prabhat Bhargava, Anbarasan Sekar, George John, Revathy Krishnamurthy, Ayushi Sahay, Palak Popat, Purvi Haria, Rima Pathak, Shalaka Joshi, Tabassum Wadasadawala, Rajiv Sarin, Sudeep Gupta, Sushmita Rath","doi":"10.4103/ijc.ijc_361_26","DOIUrl":"10.4103/ijc.ijc_361_26","url":null,"abstract":"<p><strong>Background: </strong>Hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 - EBC patients treated at a tertiary cancer center in India.</p><p><strong>Methods: </strong>This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 - EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3-4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3-4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months.</p><p><strong>Conclusion: </strong>In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 - EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"180-185"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer in the young: A real-world experience.","authors":"Rachana Chennamaneni, Meher L Konatam, Sadashivudu Gundeti, Stalin B Chowdary","doi":"10.4103/ijc.ijc_152_25","DOIUrl":"https://doi.org/10.4103/ijc.ijc_152_25","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer ranks as the fifth most prevalent malignancy worldwide. Although predominantly affecting individuals aged 50-70 years, a small proportion presents at a younger age, often displaying distinct biological behavior and adverse outcomes. We assessed the clinicopathological characteristics and outcomes of young patients with gastric cancer and compared them with those of older individuals.</p><p><strong>Methods: </strong>A retrospective analysis of gastric cancer patients diagnosed between 2018 and 2022 at a tertiary cancer center compared younger (<45 years) and older (≥45 years) groups across demographic, pathological, treatment, and survival variables. Kaplan-Meier analysis assessed disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>Among 296 patients, 147 (49.6%) were ≤45 years, with a median age of 40 years. Male predominance was less evident among younger patients (1.45:1 versus 3.65:1, P = 0.0003). Younger patients had more high-grade tumors ( P = 0.0018) and peritoneal metastases. The 3-year DFS and OS in young and older patients with localized disease were 32%, 38% and 33%, 38%, respectively ( P = 0.8338 and P = 0.7713, respectively). The 3-year PFS and OS of young and older patients with metastatic disease were 11%, 14% and 8%, 12%, respectively ( P = 0.5756 and P = 0.8072, respectively).</p><p><strong>Conclusion: </strong>Nearly 40% of patients were below 45 years. Despite a higher prevalence of aggressive features and metastatic presentation, survival outcomes were similar across age groups when managed with comparable treatment protocols.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"173-179"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of oral melatonin on sleep quality, fatigue, and caregiver sleep perception in patients with head and neck cancer: A randomized double-blind placebo-controlled trial.","authors":"Pushpa, Madhu Dayal, Sakshi Khandelwal, Rohan Khandelwal, Rahul Sharma, Ankush Garg","doi":"10.4103/ijc.ijc_458_26","DOIUrl":"10.4103/ijc.ijc_458_26","url":null,"abstract":"<p><strong>Background: </strong>Sleep disturbances and fatigue are common in patients with head and neck cancer and adversely affect quality of life. Melatonin may improve sleep quality with minimal adverse effects. This study evaluated the effect of oral melatonin on sleep quality, fatigue, and caregiver sleep perception in patients with head and neck cancer.</p><p><strong>Methods: </strong>In this prospective, randomised, placebo-controlled trial, 70 patients aged 18-65 years with head and neck cancer and sleep disturbances for >1 month were randomised to oral melatonin 3 mg (Group M, n = 35) or multivitamin (placebo) (Group P, n = 35) once daily for 14 days. Pittsburgh sleep quality index (PSQI), fatigue assessment scale (FAS), and satisfaction, alertness, timing, efficiency, and duration scores were assessed at baseline and day 14.</p><p><strong>Results: </strong>Day-14 PSQI scores were lower in Group M than Group P (8.11 ± 1.55 versus 9.66 ± 1.83; P = 0.0003), with significant improvement only in Group M ( P < 0.001). FAS scores were also lower in Group M (12.66 ± 2.44 versus 14.69 ± 1.94; P = 0.0003). Caregiver sleep perception improved significantly with melatonin ( P < 0.0001).</p><p><strong>Conclusion: </strong>Oral melatonin improved sleep quality and reduced fatigue in patients with head and neck cancer and was associated with better caregiver sleep perception.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"134-139"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of preoperative repair area of thyroid gland flap in patients with neck cancer by three-dimensional imaging.","authors":"Bo Han, Ye Wang, Xiang Zhuang","doi":"10.4103/ijc.ijc_172_24","DOIUrl":"10.4103/ijc.ijc_172_24","url":null,"abstract":"<p><strong>Background: </strong>We aimed to explore a method to measure the preoperative repair area of the thyroid gland flap (TGF) in patients with neck cancer.</p><p><strong>Methods: </strong>A total of 82 patients with nonthyroid diseases were included in this study. The digital imaging and communications in medicine (DICOM) data of enhanced computed tomography (CT) of the neck were collected. Three-dimensional (3D) reconstruction was performed using Mimics software, and data on the thyroid gland was collected. The projected area of the unilateral glandular lobe was measured. The demographic data of the patients, such as sex, age, height, and body mass index, were collected. The influencing factors for the repair area of TGF were analyzed.</p><p><strong>Results: </strong>As a pedicled flap, the left thyroid lobe could provide a repair area of 7.27 ± 2.00 cm 2 , and the right thyroid lobe could provide 8.09 ± 2.06 cm 2 . A statistically positive correlation was found between the aforementioned area and patients' height ( P < 0.05).</p><p><strong>Conclusion: </strong>The preoperative repair area of TGF could be measured using enhanced CT and 3D reconstruction for patients with neck tumors. 3D reconstruction can be used to perform preoperative evaluation of TGF application.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"166-172"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148827968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of acute lymphoblastic leukemia in children and young adults treated with a Berlin-Frankfurt-Münster-based protocol in a tertiary care multispecialty government hospital.","authors":"Anupama S Borker, Darshan J Kanani","doi":"10.4103/ijc.ijc_244_26","DOIUrl":"10.4103/ijc.ijc_244_26","url":null,"abstract":"<p><strong>Background: </strong>While the survival of childhood acute lymphoblastic leukemia (ALL) approaches 90% in developed nations, outcomes in developing countries are much lower.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of the first 50 patients aged <25 years with newly diagnosed ALL who were treated with a modified Berlin-Frankfurt-Münster (BFM)-2009 protocol at our tertiary care government hospital between May 2020 and December 2024. All patients were followed up until December 2025.</p><p><strong>Results: </strong>The median age was 6 years with a male-to-female ratio of 1.5:1. Thirty-six patients had pre-B-cell ALL and 14 had T-cell ALL. On day 8, seven patients (14%) had poor prednisone response and 43 (86%) had good prednisone response. The complete remission rate at the end of induction was 94%. Forty-three patients (86%) achieved measurable residual disease negative status. According to BFM-2009 stratification, 12 were standard risk (SR), 30 were intermediate risk (IR), and 8 were high risk (HR). One patient abandoned treatment, seven patients relapsed, and three died of treatment-related toxicity. At 3 years, the event-free survival (EFS) and overall survival for the entire cohort were 75.2% and 78.3%, respectively. The SR, IR, and HR groups achieved an EFS of 90.0%, 73.3%, and 62.5%, respectively, at 3 years.</p><p><strong>Conclusion: </strong>The use of a modified risk-adapted Western protocol was feasible in a government hospital setting without undue toxicity or mortality.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"153-159"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistochemical expression of E-cadherin and Bcl-2 in oral squamous cell carcinoma.","authors":"Zeenat Shah, Rezhat Abbas, Mohammad S Dar, Suheel H Latoo, Owais Gowhar","doi":"10.4103/ijc.ijc_784_23","DOIUrl":"https://doi.org/10.4103/ijc.ijc_784_23","url":null,"abstract":"<p><strong>Background: </strong>The most frequent malignancy of the oral cavity is oral squamous cell carcinoma (OSCC), which accounts for up to 80-90% of all malignant neoplasms of the oral cavity. It results from the gradual accumulation of diverse genetic alterations. Alcohol use, tobacco use, betel quid chewing, human papillomavirus (HPV) and poor nutrition are significant risk factors for oral squamous cell carcinoma (OSCC). The cancer suppressor gene E-cadherin establishes a cutoff for Wnt-catenin signaling. Cell-cell adhesion is lost as a result of the Wnt signaling pathway being amplified when E-Cadherin expression is diminished. An antiapoptotic protein called B-cell lymphoma-2 (Bcl-2) interacts with and is controlled by P53. It is a component of the regulatory network that manages the cell cycle and triggers apoptosis.</p><p><strong>Methods: </strong>A retrospective study was conducted on 60 formalin-fixed, paraffin-embedded tissue blocks, comprising 20 cases each of well-differentiated, moderately differentiated, and poorly differentiated oral squamous cell carcinoma (OSCC). Diagnosis was based on hematoxylin and eosin staining, with oral mucosa serving as the control.</p><p><strong>Results: </strong>In increasing grades of OSCC, E-cadherin was downregulated and Bcl-2 was overexpressed; the difference was statistically significant.</p><p><strong>Conclusion: </strong>The relationship between E-cadherin and Bcl-2 was shown to be inverse. Both predictive and therapeutic uses of the indicators are possible.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"63 2","pages":"140-146"},"PeriodicalIF":0.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149080640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}